The CEO's open-market sale is the most notable element, but the dollar amount is small relative to market cap. The simultaneous large equity grants suggest the sales may be tax-related rather than a bearish signal. Monitor for any material news (pipeline updates, financing) that could explain the selling. The historical pattern of strong returns following insider buys does not apply here since this is a sell cluster.
Price Chart
Executive Summary
A cluster of insider selling at Artiva Biotherapeutics (ARTV) totaling $477K over the past week, led by CEO Fred Aslan ($256K open-market sale) and joined by the COO, CTO, and CMO. The selling is modest relative to the $500M market cap (~0.1%), and the cluster is dominated by open-market sales from C-suite executives, which per academic literature are weak predictors of future returns. However, the historical performance on ARTV insider-buy signals has been exceptionally strong (100% win rate at T+20, +14.5% avg return), and the cross-filing context shows a separate wave of non-cash equity grants to the same executives on Sept 8-9, suggesting the sales may be liquidity-driven to cover tax obligations or diversify after large grants. The net signal is neutral-to-slightly-bearish given the CEO's open-market sale, but the dollar amount is below the materiality threshold for a strong bearish call.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 23,429 shares at $10.92 for $256K on Sept 8.
- COO Jennifer Bush sold 8.4K shares at $11.16 for $94K on Sept 3.
- CTO Christopher Horan sold 10.4K shares at $11.16 for $116K on Sept 3.
- CMO Subhashis Banerjee sold 1.1K shares at $11.16 for $12K on Sept 3.
- Total cluster value of $477K represents ~0.1% of $500M market cap.
- Separate non-cash equity grants totaling 651K shares were awarded to the same executives and directors on Sept 8-9.
- Historical insider-buy signals on ARTV have a 100% T+20 win rate with +14.5% avg return, but this is a sell cluster, not a buy cluster.
Financial Impact
Total insider selling of $477K, representing ~0.1% of market cap. Non-cash equity grants of 651K shares at $0 have no immediate economic impact.
Risk Factors
- CEO open-market sale could signal lack of confidence if followed by additional selling.
- Equity grants create future dilution overhang (651K shares, ~1.3% of outstanding at current price).
- No open-market buying from any insider to offset the selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789426878703 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access